Vaccine
Volume 28, Issue 43  pp. 6943-7136 (8 October 2010)

Global use of Haemophilus influenzae type b conjugate vaccine

Original Research Article
Pages 7117-7122
Linda R. Ojo, Rosalyn E. O’Loughlin, Adam L. Cohen, Jennifer D. Loo, Karen M. Edmond, Sharmila S. Shetty, Allyson P. Bear, Lois Privor-Dumm, Ulla K. Griffiths, Rana Hajjeh

Abstract
Haemophilus influenzae type b (Hib) conjugate vaccines have been underutilized globally. We report progress in global use of Hib vaccines included in national immunization schedules. The number of countries using Hib vaccine increased from 89/193 (46%) in 2004 to 158/193 (82%) by the end of 2009. The increase was greatest among low-income countries eligible for financial support from the GAVI Alliance [13/75 (17%) in 2004, 60/72 (83%) by the end of 2009], and can be attributed to various factors. Additional efforts are still needed to increase vaccine adoption in lower middle income countries [20/31 (65%) by the end of 2009].